about
Role of thiamine pyrophosphate in oligomerisation, functioning and import of peroxisomal 2-hydroxyacyl-CoA lyaseBreakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase: a revised pathway for the alpha-oxidation of straight chain fatty acidsInsights into European drug shortages: a survey of hospital pharmacistsIndustry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology DrugsManaged Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the FuturePresence of thiamine pyrophosphate in mammalian peroxisomes.Alpha-oxidation of 3-methyl-substituted fatty acids and its thiamine dependence.Drug shortages in European countries: a trade-off between market attractiveness and cost containment?Sponsorship in non-commercial clinical trials: definitions, challenges and the role of Good Clinical Practices guidelines.Toward a European definition for a drug shortage: a qualitative study.Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory studyIt is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North-South collaborative trials.Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.Call for a dedicated European legal framework for bacteriophage therapy.Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy.Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.Market access of cancer drugs in European countries: improving resource allocation.Clinical, Economic and Policy Implications of Drug Shortages in the European Union.Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.Time Investment in Drug Supply Problems by Flemish Community Pharmacies.Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease?Thiamine pyrophosphate: an essential cofactor in the mammalian metabolism of 3-methyl-branched fatty acids--implications for thiamine deficiencies?Osteoporosis after combined use of a neuroleptic and antidepressants.Financial based agreements and performance based agreements: the Belgian experience.Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial.Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.Development and implementation of "Check of Medication Appropriateness" (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillanceEvaluation of drotrecogin alpha use in a Belgian university hospitalCauses of drug shortages in the legal pharmaceutical frameworkThe necessity for a European definition of drug shortagesHigh-risk medication in community care: a scoping reviewSharing of Clinical Trial Data and Samples: The Cancer Patient PerspectiveWhat Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
P50
Q24307970-8E1EAC7C-9FF0-4C4D-918A-2F90E6FF8FFCQ24337847-2164F0AD-1234-42F7-B17C-D36F57FEA5A4Q28544114-78E57B82-CA02-4614-B6E0-FA419B99B4E4Q30383258-76AC131C-8E51-48DE-8889-B932008EAC08Q30843820-CF28F5D9-CCF7-4958-AFEE-EC0362F14722Q33289079-246CC7E6-AF0D-4055-85B6-4CA3E44FBD47Q33965455-5DFCEEC0-C31A-446D-B4B1-D340A05318D4Q34677617-F1D2BDE6-24EA-4A15-8F79-3F48897F6021Q35881241-8278293C-436A-4B74-996E-799C016E4EA3Q36226420-0B76FF54-D3A5-4F38-A81C-F24197339FD7Q36325432-E5869C09-8A69-49DE-9F75-C48B2746FEB4Q36394552-6D2EF91E-854C-4810-B435-38938072BBF5Q37281307-2B1E795F-B382-471C-BC4C-B57AFEE1AA24Q37631618-F543D298-BB34-4C9B-BDF0-149C6B03AC53Q37790007-45E8EDA4-9C24-49B9-8D0F-80CCAD76206CQ38004869-2B3ECC6F-D759-491D-A3DB-267C4172DC14Q38163486-EA30BF0F-2C31-496B-9404-69E7F5259E44Q39536773-6FB529BE-679E-4796-9047-416F5EEE77B4Q40461427-0FC55FC3-08E6-4EFC-B3C2-92C230597F23Q41526726-434B17BA-167A-4105-8E2A-3264CD42AF27Q42320882-AEA35CBD-D5A9-4A63-8C84-ACDD89A590A9Q44552180-AE308458-F5C8-4CAA-8111-E01D5C3DA118Q44720561-3CF88865-9F2F-4317-A844-5BC7303C1F80Q46522591-7F05ED4C-A0D3-48D9-AA03-2BAACFEDCD98Q49162947-C3D26443-F133-4156-9C19-113C1EF4A988Q49832422-639717DA-67D4-41F4-9E4B-6A294392A654Q50918560-D664C7FA-32DA-400A-8967-DD0B411039A4Q64237264-B4C9D643-6E3E-4F09-9D3A-E43B9E6957AEQ79366480-DCF9F4EF-1D63-43DB-99F2-2677B8615F22Q86537961-A3B220D8-7619-4AA1-9428-A3AB5D06A719Q89418853-8A50B8C9-E383-4972-98EC-1BF4F6E35EB5Q89561742-20E7F230-C5BF-4B78-B11F-455D95F598E8Q89967729-3B12A769-9EE3-486A-A01C-BB44C7812091Q92269402-890046E3-EB36-4E37-85D9-BDC6189245E4
P50
description
researcher
@en
wetenschapper
@nl
name
Minne Casteels
@en
Minne Casteels
@nl
type
label
Minne Casteels
@en
Minne Casteels
@nl
prefLabel
Minne Casteels
@en
Minne Casteels
@nl
P31
P496
0000-0001-9401-5489